FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1520954009> ?p ?o ?g. }

• W1520954009 endingPage "553" @default.
• W1520954009 startingPage "545" @default.
• W1520954009 abstract "Atazanavir (ATV) boosted with ritonavir (ATV/r) is a potent, well-tolerated, once-daily protease inhibitor (PI). Few data are available on this agent as a treatment simplification option for patients taking other PIs.The aim of the study was to determine the effectiveness and safety of ATV-containing regimens in patients who have simplified their antiretroviral treatment.SIMPATAZ was a multicentre, prospective, noninterventional study in patients who had undetectable HIV RNA on their current PI-containing therapy and who were switched to an ATV/r-based regimen. Patients underwent a routine physical examination, and data were collected on HIV RNA levels, CD4 cell counts, liver function, lipid parameters, adverse reactions, adherence to treatment and patient satisfaction.A total of 183 patients were enrolled in the study and included in the analysis (80% were male, 29% had AIDS, and 52% were coinfected with HIV and hepatitis B virus or hepatitis C virus). The median baseline CD4 count was 514 cells/μL. Median exposure to previous HIV therapy was 8 years, and 32% of patients had a history of PI failures. Lopinavir boosted with ritonavir was the most frequent PI replaced (62%) and tenofovir+lamivudine /emtricitabine the backbone most used during the study (29%). The study drug was discontinued early by 25 patients (14%), two of whom discontinued as a result of adverse events (Hodgkin lymphoma and vomiting). Two patients died (lung cancer and myocardial infarction). At month 12, 93% of the study population had an undetectable HIV RNA viral load. Hyperbilirubinaemia >3 mg/dL and increased alanine aminotransferase levels>200 IU/L were observed in 38.5% and 4.4% of patients, respectively. Median changes from baseline to month 12 in total cholesterol, triglycerides and low-density lipoprotein cholesterol were -13 mg/dL (-7%; P<0.0001), -19 mg/dL (-13%; P<0.0001) and -7 mg/dL (-6%; P=0.021), respectively.In a real-world setting, switching from other PIs to ATV/r is a well-tolerated and safe option for improving the lipid profile and for retaining virological response in controlled pretreated patients." @default.
• W1520954009 created "2016-06-24" @default.
• W1520954009 creator A5001003748 @default.
• W1520954009 creator A5001777475 @default.
• W1520954009 creator A5004111801 @default.
• W1520954009 creator A5007743718 @default.
• W1520954009 creator A5013220888 @default.
• W1520954009 creator A5015147550 @default.
• W1520954009 creator A5019841865 @default.
• W1520954009 creator A5023090633 @default.
• W1520954009 creator A5023312068 @default.
• W1520954009 creator A5031440229 @default.
• W1520954009 creator A5039216626 @default.
• W1520954009 creator A5041078659 @default.
• W1520954009 creator A5042618056 @default.
• W1520954009 creator A5047431390 @default.
• W1520954009 creator A5052052563 @default.
• W1520954009 creator A5071736206 @default.
• W1520954009 creator A5076780201 @default.
• W1520954009 creator A5076928079 @default.
• W1520954009 creator A5084032137 @default.
• W1520954009 creator A5086158594 @default.
• W1520954009 date "2010-09-03" @default.
• W1520954009 modified "2023-10-16" @default.
• W1520954009 title "Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions" @default.
• W1520954009 cites W1966067024 @default.
• W1520954009 cites W2045131275 @default.
• W1520954009 cites W2057394385 @default.
• W1520954009 cites W2058550365 @default.
• W1520954009 cites W2096913750 @default.
• W1520954009 cites W2113643689 @default.
• W1520954009 cites W2123063127 @default.
• W1520954009 cites W2151420123 @default.
• W1520954009 cites W2318289184 @default.
• W1520954009 doi "https://doi.org/10.1111/j.1468-1293.2010.00827.x" @default.
• W1520954009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20345884" @default.
• W1520954009 hasPublicationYear "2010" @default.
• W1520954009 type Work @default.
• W1520954009 sameAs 1520954009 @default.
• W1520954009 citedByCount "15" @default.
• W1520954009 countsByYear W15209540092012 @default.
• W1520954009 countsByYear W15209540092013 @default.
• W1520954009 countsByYear W15209540092016 @default.
• W1520954009 countsByYear W15209540092020 @default.
• W1520954009 crossrefType "journal-article" @default.
• W1520954009 hasAuthorship W1520954009A5001003748 @default.
• W1520954009 hasAuthorship W1520954009A5001777475 @default.
• W1520954009 hasAuthorship W1520954009A5004111801 @default.
• W1520954009 hasAuthorship W1520954009A5007743718 @default.
• W1520954009 hasAuthorship W1520954009A5013220888 @default.
• W1520954009 hasAuthorship W1520954009A5015147550 @default.
• W1520954009 hasAuthorship W1520954009A5019841865 @default.
• W1520954009 hasAuthorship W1520954009A5023090633 @default.
• W1520954009 hasAuthorship W1520954009A5023312068 @default.
• W1520954009 hasAuthorship W1520954009A5031440229 @default.
• W1520954009 hasAuthorship W1520954009A5039216626 @default.
• W1520954009 hasAuthorship W1520954009A5041078659 @default.
• W1520954009 hasAuthorship W1520954009A5042618056 @default.
• W1520954009 hasAuthorship W1520954009A5047431390 @default.
• W1520954009 hasAuthorship W1520954009A5052052563 @default.
• W1520954009 hasAuthorship W1520954009A5071736206 @default.
• W1520954009 hasAuthorship W1520954009A5076780201 @default.
• W1520954009 hasAuthorship W1520954009A5076928079 @default.
• W1520954009 hasAuthorship W1520954009A5084032137 @default.
• W1520954009 hasAuthorship W1520954009A5086158594 @default.
• W1520954009 hasBestOaLocation W15209540091 @default.
• W1520954009 hasConcept C126322002 @default.
• W1520954009 hasConcept C142462285 @default.
• W1520954009 hasConcept C197934379 @default.
• W1520954009 hasConcept C203014093 @default.
• W1520954009 hasConcept C2522874641 @default.
• W1520954009 hasConcept C2777182164 @default.
• W1520954009 hasConcept C2777869810 @default.
• W1520954009 hasConcept C2778414717 @default.
• W1520954009 hasConcept C2779298103 @default.
• W1520954009 hasConcept C2779778239 @default.
• W1520954009 hasConcept C2780593183 @default.
• W1520954009 hasConcept C2781143361 @default.
• W1520954009 hasConcept C2781413609 @default.
• W1520954009 hasConcept C2908647359 @default.
• W1520954009 hasConcept C2993143319 @default.
• W1520954009 hasConcept C3013748606 @default.
• W1520954009 hasConcept C71924100 @default.
• W1520954009 hasConcept C90924648 @default.
• W1520954009 hasConcept C99454951 @default.
• W1520954009 hasConceptScore W1520954009C126322002 @default.
• W1520954009 hasConceptScore W1520954009C142462285 @default.
• W1520954009 hasConceptScore W1520954009C197934379 @default.
• W1520954009 hasConceptScore W1520954009C203014093 @default.
• W1520954009 hasConceptScore W1520954009C2522874641 @default.
• W1520954009 hasConceptScore W1520954009C2777182164 @default.
• W1520954009 hasConceptScore W1520954009C2777869810 @default.
• W1520954009 hasConceptScore W1520954009C2778414717 @default.
• W1520954009 hasConceptScore W1520954009C2779298103 @default.
• W1520954009 hasConceptScore W1520954009C2779778239 @default.
• W1520954009 hasConceptScore W1520954009C2780593183 @default.
• W1520954009 hasConceptScore W1520954009C2781143361 @default.
• W1520954009 hasConceptScore W1520954009C2781413609 @default.

• next